× Revenue includes Marketed drugs plus Phase III and Pre-Registration candidates expected to launch by 2028. Pituitary tumor leads at $892M (-8.6% CAGR), driven by lanreotide (Somatuline). Three aging drugs dominate the decline: bevacizumab (Avastin) dropped from $5.3B to $762M across GBM and glioma as biosimilars entered; methylprednisolone (Medrol) fell from $402M to $180M across cerebral edema and brain tumor; and lanreotide declined from $1.4B to $877M. The few growing indications — hemifacial spasm and low-grade glioma — are driven by Botox and BRAF/MEK targeted therapy respectively.